How early is the atherosclerotic risk in rheumatoid arthritis?

Autoimmunity Reviews

Volumn 9, Issue 10, 2010, Pages 701-707

  Bartoloni, Elena ^a   Alunno, Alessia ^a   Bistoni, Onelia ^a   Gerli, Roberto ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Biologic therapy; Cardiovascular risk factors; Early rheumatoid arthritis; Immune dysregulation; Inflammation; Subclinical atherosclerosis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELLULAR IMMUNITY; ENDOTHELIAL STEM CELL; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; HYPERLIPIDEMIA; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LIFE EXPECTANCY; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STEM CELL;

AGE OF ONSET; ANIMALS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; AUTOANTIBODIES; CLINICAL TRIALS AS TOPIC; CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; HLA-DR ANTIGENS; HUMANS; IMMUNOTHERAPY; INFLAMMATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; RISK FACTORS; SMOKING;

EID: 77955267766     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.06.001     Document Type: Review

References (80)

1. van Halm V.P., Peters M.J., Voskuyl A.E., Boers M., Lems W.F., Visser M., et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease, a cross-sectional study: the CARRE Investigation. Ann Rheum Dis 2009, 68:1395-1400.
2. Peters M.J., van Halm V.P., Voskuyl A.E., Smulders Y.M., Boers M., Lems W.F., et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009, 61:1571-1579.
3. Shoenfeld Y., Gerli R., Doria A., Matsuura E., Cerinic M.M., Ronda N., et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005, 112:3337-3347.
4. Nurmohamed M.T. Cardiovascular risk in rheumatoid arthritis. Autoimmun Rev 2009, 8:663-667.
5. Ku I.A., Imboden J.B., Hsue P.Y., Ganz P. Rheumatoid arthritis - a model of systemic inflammation driving atherosclerosis. Circ J 2009, 73:977-985.
6. van Schaardenburg D., Dijkmans B.A. Clinical approaches to early inflammatory arthritis. Nat Rev Rheumatol 2009, 5:627-633.
7. Young A., Koduri G., Batley M., Kulinskaya E., Gough A., Norton S., et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischemic heart disease and in pulmonary fibrosis. Rheumatology 2007, 46:350-357.
8. Maradit-Kremers H., Crowson C.S., Nicola P.J., Ballman K.V., Roger V.L., Jacobsen S.J., et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population based cohort study. Arthritis Rheum 2005, 52:402-411.
9. Naz S.M., Farragher T.M., Bunn D.K., Symmons D.P., Bruce I.N. The influence of age at symptoms onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis. Arthritis Rheum 2008, 58:985-989.
10. Radovits B.J., Fransen J., Al Shamma S., Eijsbouts A.M., van Riel P.L., Laan R.F. Excess mortality emerges after 10years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res 2010, 62:362-370.
11. Rantapää-Dahlqvist S. What happens before the onset of rheumatoid arthritis?. Curr Opin Rheumatol 2009, 21:272-278.
12. Montecucco F., Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis. Rheumatology 2009, 48:11-22.
13. Full L.E., Ruisanchez C., Monaco C. The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 2009, 11:217.
14. Myasoedova E., Gabriel S.E. Cardiovascular disease in rheumatoid arthritis: a step forward. Curr Opin Rheumatol 2010, 22:342-347.
15. Bang S.Y., Lee K.H., Cho S.K., Lee H.S., Lee K.W., Bae S.C. Smoking increases rheumatoid arthritis susceptibility in individuals carrying the HLA-DRB1 shared epitope, regardless of rheumatoid factor or anti-cyclic citrullinated peptide antibody status. Arthritis Rheum 2010, 62:369-377.
16. Szodoray P., Szabó Z., Kapitány A., Gyetvai A., Lakos G., Szántó S., et al. Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev 2010, 9:140-143.
17. Farragher T.M., Goodson N.J., Naseem H., Silman A.J., Thomson W., Symmons D., et al. Association of HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008, 58:359-369.
18. Mattey D.L., Thomson W., Ollier W.E., Batley M., Davies P.G., Gough A.K., et al. Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis. Arthritis Rheum 2007, 56:1408-1416.
19. Gonzales-Gay M.A., Gonzales-Juanatey C., Lopez-Diaz M.J., Piñeiro A., Garcia-Porrua C., Miranda-Filloy J.A., et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007, 57:125-132.
20. Gonzalez-Gay M., Gonzalez-Juanatey C., Ollier W.E. Endothelial dysfunction in rheumatoid arthritis: influence of HLA-DRB1 alleles. Autoimmun Rev 2004, 3:301-304.
21. Gonzales-Gay M.A., Llorca J., Palomino-Morales R., Gomez-Acebo I., Gonzalez-Juanatey C., Martin J. Influence of nitric oxide synthase gene polymorphisms on the risk of cardiovascular events in rheumatoid arthritis. Clin Exp Rheumatol 2009, 27:116-119.
22. Panoulas V.F., Stavropoulos-Kalinoglou A., Metsios G.S., Smith J.P., Milionis H.J., Douglas K.M., et al. Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis 2009, 204:178-183.
23. Palomino-Morales R., Gonzalez-Juanatey C., Vazquez-Rodriguez T.R., Miranda-Filloy J.A., Llorca J., Martin J., et al. Interleukin-6 gene-174 promoter polymorphism is associated with endothelial dysfunction but not with disease susceptibility in patients with rheumatoid arthritis. Clin Exp Rheumatol 2009, 27:964-970.
24. Vallvé J.C., Paredes S., Girona J., Uliaque K., Ribalta J., Hurt-Camejo E., et al. Tumor necrosis factor-α-1031T/C polymorphism is associated with smaller and more proatherogenic low density lipoprotein particles in patients with rheumatoid arthritis. J Rheumatol 2008, 35:1697-1703.
25. Palomino-Morales R., Gonzalez-Juanatey C., Vazquez-Rodriguez T.R., Torres O., Miranda-Filloy J.A., Llorca J., et al. Lack of association between macrophage migration inhibitory factor-173 gene polymorphism with disease susceptibility and cardiovascular risk in rheumatoid arthritis patients from northwestern Spain. Clin Exp Rheumatol 2010, 28:68-72.
26. van Nies J., Marques R.B., Trompet S., de Jong Z., Kurreeman F.A., Toes R.E., et al. TRAF1/C5 polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies. Arthritis Res Ther 2010, 12:R38.
27. Gerli R., Bartoloni Bocci E.B., Sherer Y., Vaudo G., Moscatelli S., Shoenfeld Y. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67:724-725.
28. Gerli R., Sherer Y., Bocci E.B., Vaudo G., Moscatelli S., Shoenfeld Y. Precocious atherosclerosis in rheumatoid arthritis. Role of traditional and disease-related cardiovascular risk factors. Ann N Y Acad Sci 2007, 1108:372-381.
29. Brady S., de Courten B., Reid C.M., Cicuttini F.M., de Courten M.P., Liew D. The role of traditional cardiovascular risk factors among patients with rheumatoid arthritis. J Rheumatol 2009, 36:34-40.
30. Gabriel S.E. Heart disease and rheumatoid arthritis: understanding the risks. Ann Rheum Dis 2009, 69:i61-i64.
31. van Halm V.P., Nielen M.M., Nurmohamed M.T., van Schaardenburg D., Reesink H.W., Voskuyl A.E., et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007, 66:184-188.
32. Georgiadis A.N., Papavasiliou E.C., Lourida E.S., Alamanos Y., Kostara C., Tselepis A.D., et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment - a prospective, controlled study. Arthritis Res Ther 2006, 8:R82.
33. Rizzo M., Spinas G.A., Cesur M., Ozbalkan Z., Rini G.B., Berneis K. Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis. Atherosclerosis 2009, 207:502-506.
34. Shahin D., Eltoraby E., Mesbah A., Houssein M. Insulin resistance in early untreated rheumatoid arthritis patients. Clin Biochem 2010, 43:661-665.
35. Chung C.P., Oeser A., Solus J.F., Gebretsadik T., Shintani A., Avalos I., et al. Inflammation associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008, 58:2105-2112.
36. Gerli R., Sherer Y., Vaudo G., Schillaci G., Gilburd B., Giordano A., et al. Early atherosclerosis in rheumatoid arthritis: effects of smoking on thickness of the carotid artery intima media. Ann N Y Acad Sci 2005, 1051:281-290.
37. Karlson E.W., Chang S.C., Cui J., Chibnik L.B., Fraser P.A., De Vivo I., et al. Gene-environment interaction between HLA-DRB1 shared epitope and heavy cigarette smoking in predicting incident rheumatoid arthritis. Ann Rheum Dis 2010, 69:54-60.
38. Baka Z., Buzàs E., Nagy G. Rheumatoid arthritis and smoking: putting the pieces together. Arthritis Res Ther 2009, 11:238.
39. Panoulas V.F., Douglas K.M., Smith J.P., Taffé P., Stavropoulos-Kalinoglou A., Toms T.E., et al. Polymorphism of the endothelin-1 gene associate with hypertension in patients with rheumatoid arthritis. Endothelium 2008, 15:203-212.
40. Panoulas V.F., Douglas K.M., Smith J.P., Stavropoulos-Kalinoglou A., Metsios G.S., Nightingale P., et al. Transforming growth factor-beta1 869T/C, but not interleukin-6-174G/C, polymorphism associates with hypertension in rheumatoid arthritis. Rheumatology 2009, 48:113-118.
41. Goodson N.J., Symmons D.P., Scott D.G., Bunn D., Lunt M., Silman A.J. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005, 52:2293-2299.
42. Rho Y.H., Chung C.P., Oeser A., Solus J., Asanuma Y., Sokka T., et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009, 61:1580-1585.
43. Karlson E.W., Chibnik L.B., Tworoger S.S., Lee I.M., Buring J.E., Shadick N.A., et al. Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies. Arthritis Rheum 2009, 60:641-652.
44. Kokkonen H., Söderström I., Rocklöv J., Hallmans G., Lejon K., Rantapää-Dahlqvist S. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 2010, 62:383-391.
45. Rantapää-Dahlqvist S., Boman K., Tarkowski A., Hallmans G. Up regulation of monocyte chemoattractant protein-1 expression in anti-citrulline antibody and immunoglobulin M rheumatoid factor positive subjects precedes onset of inflammatory response and development of overt rheumatoid arthritis. Ann Rheum Dis 2007, 66:121-123.
46. Nielen M.M., van Schaardenburg D., Reesink H.W., Twisk J.W., van de Stadt R.J., van der Horst-Bruinsma I.E., et al. Simultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritis. Ann Rheum Dis 2006, 65:535-537.
47. Liang K.P., Kremers H.M., Crowson C.S., Snyder M.R., Therneau T.M., Roger V.L., et al. Autoantibodies and the risk of cardiovascular events. J Rheumatol 2009, 36:2462-2469.
48. Sherer Y., Gerli R., Gilburd B., Bartoloni Bocci E., Vaudo G., Mannarino E., et al. Thickened carotid artery intima-media in rheumatoid arthritis is associated with elevated anticardiolipin antibodies. Lupus 2007, 16:259-264.
49. Ahmed H.M., Youssef M., Mosaad Y.M. Antibodies against oxidized low-density lipoprotein are associated with subclinical atherosclerosis in recent-onset rheumatoid arthritis. Clin Rheumatol 2010, Electronic publication head of print.
50. Weng N.P., Akbar A.N., Goronzy J. CD28(-) T cells: their role in the age-associated decline of immune function. Trends Immunol 2009, 30:306-312.
51. null T lymphocytes and recurrence of acute coronary events. J Am Coll Cardiol 2007, 50:1450-1458.
52. null T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004, 109:2744-2748.
53. null cells in the acceleration of atherosclerosis in rheumatoid arthritis: comment on the article by Farragher et al. Arthritis Rheum 2009, 60:631-632.
54. Werner N., Kosiol S., Schiegel T., Ahlers P., Walenta K., Link A., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005, 353:999-1007.
55. Van Zonneveld A.J., de Boer H.C., van der Veer E.P., Rabenlink T.J. Inflammation, vascular injury and repair in rheumatoid arthritis. Ann Rheum Dis 2010, 69:i57-i60.
56. Distler J.H., Beyer C., Schett G., Lüscher T., Gay S., Distler O. Endothelial progenitor cell. Novel players in the pathogenesis of rheumatic diseases. Arthritis Rheum 2009, 60:3168-3179.
57. Yiu K.H., Wang S., Mok M.Y., Ooi G.C., Khong P.L., Lau C.P., et al. Role of circulating endothelial progenitor cells in patients with rheumatoid arthritis with coronary calcification. J Rheumatol 2010, 37:529-535.
58. Pàkozdi A., Besenyei T., Paragh G., Koch A.E., Szekanecz Z. Endothelial progenitor cells in arthritis-associated vasculogenesis and atherosclerosis. Joint Bone Spine 2009, 76:581-583.
59. Khan F., Galarraga B., Belch J.J. The role of endothelial function and its assessment in rheumatoid arthritis. Nat Rev Rheumatol 2010, 6:253-261.
60. Tyrrell P.N., Beyene J., Feldman B.M., McCrindle B.W., Silverman E.D., Bradley T.J. Rheumatic disease and carotid intima-media thickness. A systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 2010, 30:1014-1026.
61. Bergholm R., Leirisalo-Repo M., Vehkavaara S., Mäkimattila S., Taskinen M.R., Yki-Järvinen H. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002, 22:1637-1641.
62. Hannawi S., Marwick T.H., Thomas R. Inflammation predicts accelerated brachial arterial wall changes in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther 2009, 11:R51.
63. Turiel M., Atzeni F., Tomasoni L., de Portu S., Delfino L., Bodini B.D., et al. Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. Rheumatology 2009, 48:834-839.
64. Turiel M., Tomasoni L., Sitia S., Cicala S., Gianturco L., Ricci C., et al. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. Cardiovasc Ther 2010, Electronic publication ahead of print.
65. Park Y.B., Ahn C.W., Choi H.K., Lee S.H., In B.H., Lee H.C., et al. Atherosclerosis in rheumatoid arthritis. Morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 2002, 46:1714-1719.
66. Hannawi S., Haluska B., Marwick T.H., Thomas R. Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther 2007, 9:R116.
67. Georgiadis A.N., Voulgari P.V., Argyropoulou M.I., Alamanos Y., Elisaf M., Tselepis A.D., et al. Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 2008, 38:13-19.
68. Chung C.P., Oeser A., Raggi P., Gebretsadik T., Shintani A.K., Sokka T., et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005, 52:3045-3053.
69. Naranjo A., Sokka I., Descalzo M.A., Calvo-Alén J., Hørslev-Petersen K., Luukkainen R.K., et al. Cardiovascular disease in patients with rheumatoid arthritis: results from QUEST-RA study. Arthritis Res Ther 2008, 10:R30.
70. Kerekes G., Soltèsz P., Dèr H., Veres K., Szabó Z., Végvári A., et al. Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann N Y Acad Sci 2009, 1173:814-821.
71. Gallaraga B., Belch J.J., Pullar T., Ogston S., Khan F. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy. J Rheumatol 2010, 37:521-528.
72. Foster W., Carruthers D., Lip G., Blann A.D. Inflammation and microvascular and macrovascular endothelial dysfunction in rheumatoid arthritis: effect of treatment. J Rheumatol 2010, 37:711-716.
73. Jick S.S., Choi H., Li L., McInnes I.B., Sattar N. Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 2009, 68:546-551.
74. McCarey D.W., McInnes I.B., Madhok R., Hampson R., Scherbakov O., Ford I., et al. Trail of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004, 363:2015-2021.
75. Toms T.E., Panoulas V.F., Douglas K.M., Griffiths H., Sattar N., Smith J.P., et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?. Ann Rheum Dis 2010, 69:683-688.
76. Peters M.J., Symmons D.P., McCarey D., Dijkmans B.A., Nicola P., Kvien T.K., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-331.
77. Gerli R., Bocci E.B., Shoenfeld Y. Effect of tumor necrosis factor alpha inhibition on CD28 surface expression on CD4+ T cells. Arthritis Rheum 2006, 54:3060-3061.
78. Gerli R., Vaudo G., Bocci E.B., Schillaci G., Alunno A., Luccioli F., et al. Functional impairment of arterial wall in primary Sjögren's syndrome: combined action of immunological and inflammatory factors. Arthritis Care Res 2010, 62:712-718.
79. Gerli R., Bartoloni E., Shoenfeld Y. Association of subclinical atherosclerosis and leukopenia in systemic autoimmune diseases. Arthritis Rheum 2010, Electronic publication head of print.
80. John H., Kitas G., Toms T., Goodson N. Cardiovascular co-morbidity in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009, 23:71-82.